ANTON OILFIELD (03337) announced its interim results, with a profit attributable to shareholders of 105 million yuan, a decrease of 36.64% compared to the same period last year.
Antong Oilfield Services (03337) announced its interim results for the six months ending June 30, 2026. The group achieved total revenue of 2.682 billion yuan (RMB, the same below), an increase of 1.94% year-on-year; profit attributable to shareholders was 105 million yuan, a decrease of 36.64% year-on-year; basic earnings per share were 0.0387 yuan.
ANTON OILFIELD (03337) announced its interim results for the six months ended June 30, 2026. The group achieved total revenue of RMB 2.682 billion, an increase of 1.94% year-on-year; the profit attributable to shareholders was RMB 105 million, a decrease of 36.64% year-on-year; basic earnings per share were RMB 0.0387.
In the first half of 2026, the groups new orders in global new markets totaled approximately RMB 1.5996 billion, a significant increase of 161.4% compared to the same period in 2025. Revenue from other overseas markets was approximately RMB 667.9 million, representing a substantial increase of about 187.4% compared to RMB 232.4 million in the same period of 2025.
Related Articles

MANULIFE-S (00945) will distribute a second-quarter dividend of CAD 0.485 per share on September 21.

BRETON (01333) expects to incur a loss of approximately 80 million to 90 million yuan in the medium term, narrowing by about 45.93% to 51.67% compared to the same period last year.

AKESO (09926): The AK112309/HARMONi-GI1 Phase III clinical trial achieved statistically significant positive results in overall survival (OS) when comparing the efficacy of Abraxane combined with gemcitabine to that of Atezolizumab combined with chemotherapy, indicating substantial clinical benefits.
MANULIFE-S (00945) will distribute a second-quarter dividend of CAD 0.485 per share on September 21.

BRETON (01333) expects to incur a loss of approximately 80 million to 90 million yuan in the medium term, narrowing by about 45.93% to 51.67% compared to the same period last year.

AKESO (09926): The AK112309/HARMONi-GI1 Phase III clinical trial achieved statistically significant positive results in overall survival (OS) when comparing the efficacy of Abraxane combined with gemcitabine to that of Atezolizumab combined with chemotherapy, indicating substantial clinical benefits.

RECOMMEND





